Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.0
3.4
Journals
Life
Special Issues
Advances in Pulmonology: Transforming Diagnosis and Treatment of Lung Diseases
share announcement

Advances in Pulmonology: Transforming Diagnosis and Treatment of Lung Diseases

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 841

Special Issue Editors

Prof. Dr. Doina-Adina Todea

E-Mail Website
Guest Editor
1. Department of Pneumology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Victor Babes Street No. 8, 400347 Cluj-Napoca, Romania
2. Leon Daniello Clinical Hospital of Pneumology, B.P. Hasdeu Street No. 6, 400332 Cluj Napoca, Romania
Interests: chronic pulmonary obstructive disease; sleep; tabacology; pulmonary infectious diseases; interstitial lung diseases; pulmonary rehabilitation; long COVID; air pollution and environmental diseases; lung cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Anca-Diana Maierean

E-Mail Website
Guest Editor
1. Department of Pneumology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Victor Babes Street No. 8, 400347 Cluj-Napoca, Romania
2. Leon Daniello Clinical Hospital of Pneumology, B.P. Hasdeu Street No. 6, 400332 Cluj Napoca, Romania
Interests: COPD; sleep disorders and comorbidities; interstitial lung disease; post-COVID-19 syndrome; thoracic surgery
Dr. Damiana-Maria Vulturar

E-Mail
Guest Editor
1. Department of Pneumology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Victor Babes Street No. 8, 400347 Cluj-Napoca, Romania
2. Leon Daniello Clinical Hospital of Pneumology, B.P. Hasdeu Street No. 6, 400332 Cluj Napoca, Romania
Interests: COPD; sleep disorders; interstitial lung disease; lung cancer; pulmonary hypertension

Special Issue Information

Dear Colleagues,

In recent years, significant advancements in pulmonology have redefined the diagnosis and treatment of lung diseases, offering patients innovative and personalized solutions. From the development of advanced biomarkers and high-resolution imaging to personalized therapies and minimally invasive interventions, ongoing research continues to improve patient outcomes.

This Special Issue aims to gather original research and reviews on the latest innovations in pulmonology. We welcome articles exploring novel diagnostic techniques; advanced biomarkers and therapies for sleep disorders, chronic obstructive pulmonary diseases, interstitial lung diseases, and lung cancer; advances in thoracic surgery; and the impact of emerging infections and environmental changes on lung health. Additionally, we encourage the submission of studies addressing digital health solutions in modern pulmonology.

Through this Special Issue, we aim to foster knowledge exchange among researchers and clinicians, contributing to the development of effective strategies to enhance patient care in pulmonary medicine.

Prof. Dr. Doina-Adina Todea
Dr. Anca-Diana Maierean
Dr. Damiana-Maria Vulturar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers in lung diseases
  • sleep disorders
  • chronic obstructive diseases
  • interstitial lung diseases
  • thoracic surgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 255 KiB  
Article
Is Biologic Therapy an Effective Tool for Achieving Remission in Severe Asthma? A Retrospective Study in Central Romania
by Corina Mărginean, Dragoș Huțanu, Mara Andreea Vultur, Hédi-Katalin Sárközi, Edith-Simona Ianoși, Maria Beatrice Ianoși, Andreea Safta, Gabriela Jimborean and Corina Eugenia Budin
Life 2025, 15(7), 1113; https://doi.org/10.3390/life15071113 - 16 Jul 2025
Viewed by 103
Abstract
Background: Severe asthma, which is characterized by persistent symptoms despite standard therapies, presents a significant clinical challenge. Biologic therapies targeting specific inflammatory pathways offer a potential avenue for achieving disease remission. This retrospective study evaluates the effectiveness of biologic therapies in achieving remission [...] Read more.
Background: Severe asthma, which is characterized by persistent symptoms despite standard therapies, presents a significant clinical challenge. Biologic therapies targeting specific inflammatory pathways offer a potential avenue for achieving disease remission. This retrospective study evaluates the effectiveness of biologic therapies in achieving remission in severe asthma within a central Romanian cohort. Methods: Forty-eight patients with severe asthma treated with omalizumab, benralizumab, or dupilumab (2020–2025) were assessed. Clinical remission was defined using ACT scores, exacerbation frequency, corticosteroid use, and FEV1. Biological remission was determined using FeNO and eosinophil levels. Statistical analysis was performed to compare treatment outcomes. Results: At 12 months, 75% of patients achieved biological remission, and 75% reached clinical remission criteria. Significant improvements were observed in FEV1 (p < 0.001), eosinophil counts (p < 0.001), and ACT scores (p < 0.001). Complete remission, encompassing clinical, biological, and functional normalization, was observed in 54.2% of patients. Conclusion: Biologic therapies demonstrate promise in inducing comprehensive remission in severe asthma, supporting their role in improving disease control and lung function. Further research with larger cohorts is warranted. Full article
(This article belongs to the Special Issue Advances in Pulmonology: Transforming Diagnosis and Treatment of Lung Diseases)
12 pages, 719 KiB  
Article
Differential Analysis of Hemogram Parameters and Cellular Ratios in Severe Asthma Exacerbations: A Comparative Study of Eosinophilic and Non-Eosinophilic Phenotypes
by Nicolae Demenciuc, Corina Eugenia Budin, Corina Ureche, Mircea Stoian, Teodora Nicola-Varo, Dragos-Florin Baba, Dariana-Elena Pătrîntașu and Diana Deleanu
Life 2025, 15(6), 970; https://doi.org/10.3390/life15060970 - 18 Jun 2025
Cited by 2 | Viewed by 542
Abstract
Asthma exacerbations are acute worsening episodes in individuals with bronchial asthma, frequently necessitating emergency hospital care. Early differentiation between eosinophilic (≥150 eosinophils/mm3) and non-eosinophilic (<150 eosinophils/mm3) subtypes plays a crucial role in treatment decisions and identifying patients eligible for [...] Read more.
Asthma exacerbations are acute worsening episodes in individuals with bronchial asthma, frequently necessitating emergency hospital care. Early differentiation between eosinophilic (≥150 eosinophils/mm3) and non-eosinophilic (<150 eosinophils/mm3) subtypes plays a crucial role in treatment decisions and identifying patients eligible for biologic therapies. The ExBA Study explored variations in complete blood count (CBC) parameters and derived cellular ratios—namely the neutrophil-to-lymphocyte (NLR), thrombocyte-to-lymphocyte (TLR), and eosinophil-to-leukocyte ratios (ELR)—in adults hospitalized with severe asthma exacerbations. Ninety patients were enrolled and categorized into eosinophilic (n = 38) and non-eosinophilic (n = 52) groups. Significant statistical differences were observed in the neutrophil and lymphocyte levels, as well as in all three ratios. ROC analysis highlighted the ELR as the most specific indicator of the eosinophilic phenotype (specificity 100%, AUC 0.938, cut-off 0.003), whereas the NLR and TLR showed stronger associations with the non-eosinophilic group (AUC 0.733 and 0.676). No meaningful differences emerged regarding arterial blood gas levels, length of hospital stay, treatment costs, or mortality. A notable association was found between a personal or family history of atopy and the eosinophilic subtype (p = 0.0181). This study underscores the relevance of CBC-based ratios in asthma phenotyping during exacerbation events. Full article
(This article belongs to the Special Issue Advances in Pulmonology: Transforming Diagnosis and Treatment of Lung Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop